DRYTEC
LOE ApproachingNDAINTRAVENOUS, ORALSOLUTION
Approved
Nov 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 10h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DRYTEC is an intravenous and oral solution approved by NDA in 1976 and currently marketed by GE HealthCare. The mechanism of action, indications, and pharmacologic class are not publicly disclosed in available data. This product is a legacy therapeutic with limited contemporary clinical information.
LOE Approaching
Product approaching loss of exclusivity with low-to-moderate competitive pressure (30%), indicating transition from growth to defensive commercial strategy and potential team restructuring.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
DRYTEC currently has zero linked job opportunities, reflecting its mature, legacy status with minimal hiring activity. Roles on this product focus on defending market share, managing exclusivity loss, and optimizing manufacturing and distribution efficiency rather than growth or innovation.
Product Manager (Legacy/Maintenance)Commercial Operations
Worked on DRYTEC at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.